Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma.

Ahmad JoshkonEmeline TabouretWael TraboulsiRichard BachelierStéphanie SimonciniSandrine RoffinoCarine Jiguet-JiglaireBassam BadranBenjamin GuilletAlexandrine Foucault-BertaudAurelie S LeroyerFrançoise Dignat-GeorgeOlivier ChinotHussein Fayyad-KazanNathalie BardinMarcel Blot-Chabaud

Published in: Acta neuropathologica communications (2022)

We propose sCD146 to be 1/ an early biomarker to predict and 2/ a potential target to prevent bevacizumab resistance in patients with glioblastoma.

Keyphrases

stem cells
human health
risk assessment
mesenchymal stem cells
bone marrow
cell therapy